Ireland
--:--IST
Latest
Astellas Expands Its 330 Million Euro Tralee Biopharma Facility with a Second Aseptic Filling Line to Double Drug-Product Capacity Xeolas Pharmaceuticals Opens 158,000 Sq Ft State-of-the-Art Baldoyle Facility to Scale Specialty Medicine Manufacturing Priya Life Science Partners with Fleming for the 9th Annual Corporate Compliance & Transparency in Life Sciences Summit in Zurich Ireland Has the Capital and the Lessons: Digital Project Management Is How They Become Delivery Dunbar Pharma Brings First Plant-Derived Dronabinol API to UK Market Through IPS Pharma Leveraging Priya Life Science as a Data Tracker: The Ultimate Use Case & Career Guide The €100K Reality Check: Why a Six-Figure Pharma Salary in Ireland Feels Different Than in Switzerland or Germany Ireland's €93.8 Billion Non-EU Pharma Export Engine: Trade Data, Destination Markets, and Economic Impact Astellas Expands Its 330 Million Euro Tralee Biopharma Facility with a Second Aseptic Filling Line to Double Drug-Product Capacity Xeolas Pharmaceuticals Opens 158,000 Sq Ft State-of-the-Art Baldoyle Facility to Scale Specialty Medicine Manufacturing Priya Life Science Partners with Fleming for the 9th Annual Corporate Compliance & Transparency in Life Sciences Summit in Zurich Ireland Has the Capital and the Lessons: Digital Project Management Is How They Become Delivery Dunbar Pharma Brings First Plant-Derived Dronabinol API to UK Market Through IPS Pharma Leveraging Priya Life Science as a Data Tracker: The Ultimate Use Case & Career Guide The €100K Reality Check: Why a Six-Figure Pharma Salary in Ireland Feels Different Than in Switzerland or Germany Ireland's €93.8 Billion Non-EU Pharma Export Engine: Trade Data, Destination Markets, and Economic Impact
Starting soon Not applicable

Evaluation of Calcified Coronary Lesion Preparation With the Naviscore Scoring Balloon

NCT07650578 · tracked via the Priya Life Science Spain tracker
Sponsor
University of Mons
Phase
Not applicable
Started
2026-07
Last updated
2026-06-16

Condition(s) studied

Coronary Arterial Disease (CAD)Calcific Coronary Arteriosclerosis

Investigational drug(s) / intervention(s)

Scoring Balloon PTCA CatheterNon-Compliant (NC) Angioplasty Balloon

Scoring Balloon PTCA Catheter: Percutaneous coronary preparation of calcified coronary stenosis using the rapid exchange Naviscore scoring balloon catheter before drug-eluting stent deployment. The device incorporates an over-the-balloon metallic nitinol element designed to focally concentrate dilation forces, minimizing balloon slippage and scoring the atheromatous plaque at lower pressures to facilitate optimal stent expansion. Sizing is based on a 0.8:1 to 1:1 ratio relative to the reference lumen. Operators must execute a specific sequence of inflating the scoring balloon to nominal pressure, fully deflating it, mobilizing it within the lesion, and reinflating it, repeated three to four times across the target segment to ensure multi-focal plaque disruption before stenting.

Non-Compliant (NC) Angioplasty Balloon: Conventional non-compliant (NC) PTCA balloon catheter used for standard lesion pre-dilatation according to routine clinical practice, inflated below the rated burst pressure without parallel guidewires in place.

Study summary

The purpose of this clinical study is to evaluate the effectiveness and safety of a specialized medical device, the Naviscore scoring balloon, in preparing calcified coronary artery narrowings before the implantation of a drug-eluting stent. During percutaneous coronary interventions, the presence of calcified plaques in the heart arteries represents a major challenge because it can prevent stents from expanding fully. When a stent remains under-expanded, it significantly increases the long-term risk of arterial re-narrowing or blood clot formation. To optimize stent expansion, appropriate preparation of the diseased vessel section before stent insertion is a critical phase.

This study is a prospective, multi-center randomized trial designed to test the hypothesis that treating calcified coronary lesions with the Naviscore scoring balloon will achieve a better stent expansion and a larger final minimal stent area compared to standard lesion preparation using regular non-compliant balloons. Eligible participants will be randomized in a one-to-one ratio to one of these two lesion preparation strategies. For all included patients, standard drug-eluting stents will be deployed. The study will use intravascular ultrasound imaging to evaluate the final minimum area of the stent directly inside the treated artery at the site of the highest initial calcium burden. Participant health and clinical outcomes will be monitored for up to twelve months following the procedure.

Eligibility

Sex
ALL
Min age
18 Years
Max age
—
Healthy volunteers
No
Inclusion Criteria: * Patient written consent is given, ≥18 years. * A de novo lesion to be treated in a vessel between 2.5 and 4.0 mm. * Moderate to heavily calcified lesions detected by coronary angiography on two orthogonal views, and confirmed by IVUS if the lesion can be crossed with the catheter. Exclusion Criteria: * Patient \<18 years old. * Pregnant female. * Contraindication to dual antiplatelet therapy. * Thrombocytopenia (under 100 000). * Major surgical intervention planned within one year. * Significant left main lesion. * Chronic total occlusion. * Lesion in a graft. * In-stent restenosis lesion. * Lesion responsible of a ST elevated Myocardial Infarction (STEMI)

Primary outcome measure(s)

  • Final Minimal Stent Area (MSA) — Immediately post-stenting optimization during the index percutaneous coronary intervention (PCI) procedure.
    The minimal stent area (MSA) will be measured in square millimeters by intravascular ultrasound (IVUS) after final procedural optimization. The primary comparison will evaluate the MSA specifically at the exact site of the initial heaviest calcium burden to demonstrate the superiority of the Naviscore scoring balloon over standard non-compliant (NC) balloons.

Trial sites (14)

FacilityCityRegionStatus
CHU - HELORA site Kennedy Mons Hainaut
Imelda Bonheiden Belgium
Hôpital Erasme - Cliniques universitaires de Bruxelles Brussels Belgium
Hôpital Vivalia Libramont Belgium
CHR de la Citadelle Liège Belgium
Humani CHU Charleroi - Chimay Lodelinsart Belgium
INCCI Haerz Zenter Luxembourg Luxembourg
Centro Hospitalar de Vila Nova de Gaia/Espinho Vila Nova de Gaia Portugal
Hospital de Sant Pau Barcelona Spain
Hospital Universitari de Bellvitge Barcelona Spain
Hospital Puerta Del Mar Cadiz Spain
Hospital San Pedro de Alcantara Cáceres Spain
Hospital La Fe Valencia Spain
Hospital Clínico Universitario de Valladolid Valladolid Spain
Official registry record

This page summarises publicly available registry data for informational purposes — not medical advice. Eligibility is determined by each study team; patients should discuss participation with their clinician.

View NCT07650578 on ClinicalTrials.gov ↗ ← All trials in Spain